Whitehawk Therapeutics, Inc. (WHWK) Key Metrics
WHWK valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $164.8M
- Enterprise value
- $73.2M
- P/E (TTM)
- —
- Forward P/E
- 2.7
- PEG ratio
- —
- Price / sales
- 30.0 10-yr median 17.8
- Price / book
- 1.2 10-yr median 1.4
- EV / EBITDA
- 9.4
- Dividend yield
- —
- Beta
- 0.91
WHWK key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsWHWK valuation Price multiples at each fiscal year-end price.
Price / sales+538.6%
21.0
2025 · hover or tap a bar for each year
20192025
Price / book−32.4%
1.1
2025 · hover or tap a bar for each year
20192025
Free cash flow yield+6.3 pts
−65.4%
2025 · hover or tap a bar for each year
20192025
WHWK returns How much profit the business earns on the capital it uses.
Return on equity+59.0 pts
−21.8%
2025 · hover or tap a bar for each year
20192025
Return on assets+44.2 pts
−18.6%
2025 · hover or tap a bar for each year
20192025
Asset turnover−74.8%
0.06
2025 · hover or tap a bar for each year
20192025
WHWK per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−88.0%
$0.12
2025 · hover or tap a bar for each year
20192025
Earnings per share
−$0.33
2025 · hover or tap a bar for each year
20192025
Free cash flow per share
−$1.58
2025 · hover or tap a bar for each year
20192025
Book value per share+13.4%
$2.20
2025 · hover or tap a bar for each year
20192025
Shares outstanding+129.0%
61.9M
2025 · hover or tap a bar for each year
20192025
WHWK financial health Debt, liquidity and how easily interest is covered.
Net debt−$99.3M
−$145.7M
2025 · hover or tap a bar for each year
20192025
Current ratio+185.9%
10.26
2025 · hover or tap a bar for each year
20192025
WHWK efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+71 days
151 days
2025 · hover or tap a bar for each year
20192025
Days payables outstanding+711 days
739 days
2025 · hover or tap a bar for each year
20192025
Cash conversion cycle+595 days
687 days
2025 · hover or tap a bar for each year
20192025
Capex / revenue+1.4 pts
7.7%
2025 · hover or tap a bar for each year
20192025
WHWK valuation history
Fiscal year-endToday7-year median
WHWK returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
WHWK debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
WHWK cash returned to shareholders
DividendsBuybacksFree cash flow
WHWK price vs earnings per share
Share price at year-endEPS (right axis)
WHWK key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $149.8M | $85.3M | $54.4M | $288.8M | — | $259.2M | — |
| Enterprise value | $4.1M | $38.9M | −$53.2M | $117.9M | — | $265.0M | — |
| Price / sales | 21.0 | 3.3 | 2.2 | 19.0 | — | 17.8 | — |
| Price / book | 1.1 | 1.6 | 0.5 | 1.8 | — | — | — |
| EV / sales | 0.6 | 1.5 | -2.2 | 7.7 | — | 18.2 | — |
| Earnings yield | −13.8% | −74.7% | −120.9% | −21.0% | — | −1.3% | — |
| Free cash flow yield | −65.4% | −71.8% | −117.0% | −17.3% | — | −4.9% | — |
| Dividend yield | — | — | — | 0.0% | — | 0.0% | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | — | 0.0% | — |
| Share price at fiscal year-end | $2.42 | $3.15 | $2.02 | $12.83 | $24.15 | $14.70 | $9.35 |
| Per share | |||||||
| Revenue per share | $0.12 | $0.96 | $0.90 | $0.68 | — | $0.83 | — |
| Earnings per share | −$0.33 | −$2.36 | −$2.44 | −$2.69 | — | −$0.20 | — |
| Operating cash flow per share | −$1.57 | −$2.20 | −$2.22 | −$2.21 | — | −$0.72 | — |
| Free cash flow per share | −$1.58 | −$2.26 | −$2.36 | −$2.22 | — | −$0.72 | — |
| Cash per share | $2.35 | $1.75 | $4.04 | $7.67 | — | $0.25 | — |
| Book value per share | $2.20 | $1.94 | $3.91 | $7.04 | — | −$0.71 | — |
| Tangible book value per share | $2.20 | $1.94 | $3.91 | $7.04 | — | −$0.71 | — |
| Dividends per share | — | — | — | $0.00 | — | $0.00 | — |
| Capex per share | $0.01 | $0.06 | $0.15 | $0.02 | — | $0.00 | — |
| Debt per share | — | $0.03 | $0.05 | $0.07 | — | $0.58 | — |
| Shares outstanding | 61.9M | 27.0M | 26.9M | 22.5M | — | 17.6M | — |
| Change in shares outstanding | +129.0% | +0.4% | +19.6% | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −21.8% | −80.8% | −49.9% | −41.1% | −177.6% | — | — |
| Return on assets (ROA) | −18.6% | −62.8% | −41.5% | −35.4% | −124.6% | −19.6% | −73.6% |
| Return on tangible assets | −13.7% | −90.6% | −49.7% | −32.8% | −71.4% | −18.5% | −73.6% |
| Free cash flow margin | — | −235.6% | −261.3% | −329.2% | — | −87.1% | — |
| Financial health | |||||||
| Total debt | — | $833,000 | $1.3M | $1.7M | $605,000 | $10.3M | $8.5M |
| Cash & short-term investments | $145.7M | $47.2M | $108.8M | $172.6M | $149.0M | $4.5M | $16.0M |
| Net debt | −$145.7M | −$46.4M | −$107.6M | −$170.9M | −$148.4M | $5.8M | −$7.5M |
| Debt / equity | — | 0.02 | 0.01 | 0.01 | 0.00 | — | — |
| Debt / assets | — | 0.01 | 0.01 | 0.01 | 0.00 | 0.54 | 0.51 |
| Current ratio | 10.26 | 3.59 | 4.72 | 9.56 | 9.90 | 0.62 | 0.64 |
| Quick ratio | 10.26 | 3.28 | 4.48 | 9.46 | 9.90 | 0.62 | 0.64 |
| Interest coverage | — | -438.0 | -311.4 | -272.5 | -167.2 | -3.1 | -145.0 |
| Working capital | $134.5M | $44.2M | $98.2M | $161.2M | $136.0M | −$11.4M | −$9.3M |
| Invested capital | −$9.4M | $6.1M | −$2.4M | −$12.5M | −$12.0M | −$6.6M | −$16.6M |
| Tangible asset value | $136.3M | $52.5M | $105.2M | $158.4M | $132.6M | −$12.4M | −$9.1M |
| Net current asset value | $134.5M | $43.4M | $97.4M | $154.2M | $129.8M | −$12.6M | −$9.4M |
| Graham net-net per share | $2.12 | $1.35 | $3.30 | $6.62 | — | −$0.92 | — |
| Capital allocation | |||||||
| Dividends paid | — | — | — | $0 | $4.4M | $0 | — |
| Capex / revenue | 7.7% | 6.4% | 16.3% | 2.9% | 4.1% | 0.0% | 4.8% |
| Capex / depreciation | 6.99 | 8.57 | 23.50 | 2.79 | 0.44 | 0.00 | 5.98 |
| Stock-based compensation / revenue | 138.2% | 41.7% | 49.1% | 63.4% | 188.0% | 1.0% | 14.2% |
| R&D / revenue | 1,273.1% | 196.4% | 200.9% | 214.7% | 1,756.2% | 102.9% | 1,477.2% |
| SG&A / revenue | 417.4% | 141.4% | 182.9% | 264.0% | 1,652.8% | 14.5% | 247.6% |
| Efficiency | |||||||
| Days sales outstanding | 150.8 | 80.0 | 55.1 | 22.3 | 2,305.5 | 180.7 | 138.8 |
| Days of inventory on hand | — | 39.6 | 29.2 | 10.0 | — | — | — |
| Days payables outstanding | 738.6 | 27.2 | 33.2 | 53.5 | 81.9 | 67.7 | 104.8 |
| Cash conversion cycle (days) | 687.5 | 92.4 | 51.1 | -21.1 | 2,223.6 | 112.9 | 34.0 |
| Receivables turnover | 2.42 | 4.56 | 6.63 | 16.34 | 0.16 | 2.02 | 2.63 |
| Payables turnover | 0.49 | 13.42 | 10.99 | 6.83 | 4.45 | 5.39 | 3.48 |
| Inventory turnover | — | 9.21 | 12.49 | 36.54 | — | — | — |
| Asset turnover | 0.06 | 0.26 | 0.15 | 0.09 | 0.01 | 0.82 | 0.04 |
| Average receivables | $3.0M | $5.7M | $3.7M | $931,000 | $7.1M | $7.2M | $284,896 |
| Average payables | $1.5M | $4.0M | $4.7M | $5.0M | $4.4M | $2.8M | $3.2M |
| Average inventory | $2.7M | $5.9M | $4.1M | $930,500 | $0 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 2.4% | 0.0% | 0.0% |
Computed from WHWK's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
WHWK valuation and financial ratios
Whitehawk Therapeutics earned a return on equity of −21.8% in fiscal 2025.
See the WHWK income statement, the WHWK chart for price history, or the WHWK stock overview for the latest quote and news.
WHWK key metrics FAQ
What is Whitehawk Therapeutics's return on equity?
Whitehawk Therapeutics's return on equity (ROE) was −21.8% in fiscal 2025: net income of -$20.6 million on average shareholders' equity of $94.4 million.
What is Whitehawk Therapeutics's free cash flow yield?
Whitehawk Therapeutics generated -$98.0 million of free cash flow in fiscal 2025, a free cash flow yield of −65.4% on its market value at year-end ($149.8 million).
What is Whitehawk Therapeutics's current ratio?
Whitehawk Therapeutics's current ratio was 10.26 at the end of fiscal 2025: current assets were 10.26 times current liabilities.